French pharma Servier said Tuesday that sevasemten, which it bought in June for $1.55 billion in cash plus about $1 billion in milestones, did not slow Becker muscular dystrophy in the placebo-controlled Phase 3 GRAND CANYON trial. The disease has no approved treatments; the Edgewise-origin drug had